

PHARMACEUTICAL 2023



ENANTA PHARMACEUTICALS INC Rank 99 of 446







RealRate

PHARMACEUTICAL 2023



ENANTA PHARMACEUTICALS INC Rank 99 of 446

The relative strengths and weaknesses of ENANTA PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENANTA PHARMACEUTICALS INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 54% points. The greatest weakness of ENANTA PHARMACEUTICALS INC is the variable Research and Development, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 200%, being 157% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	311,713
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	29,827
Liabilities, Non-Current	22,826
Other Assets	57,524
Other Compr. Net Income	-3,342
Other Expenses	-433
Other Liabilities	1,423
Other Net Income	1,656
Other Revenues	86,160
Property and Equipment	6,173
Research and Development	164,522
Selling, General and Administrative Expense	45,482

Output Variable	Value in 1000 USD
Assets	375,410
Liabilities	54,076
Expenses	209,571
Revenues	86,160
Stockholders Equity	321,334
Net Income	-121,755
Comprehensive Net Income	-123,426
Economic Capital Ratio	200%

